An evaluation of the safety of Crodamol PMP.
Crodamol PMP (polyoxypropylene (2) myristyl ether propionate) has been extensively employed for many years in a wide variety of human cosmetics in the absence of reported adverse reactions. The compound is being considered for use as a vehicle for veterinary pharmaceuticals in food-producing animals. This paper reviews information on the chemistry, metabolism, and toxicity of this compound, including the details of a recently completed multi-dose study in rats. Based upon this information, it is concluded that Crodamol PMP is a substance of apparently low toxic potential. Potential new uses of this compound must compare the likely exposure to the substance with the available toxicity information.
Bernard
B K
BK
SRA International, Inc., Washington, DC, USA.
Harris
J E
JE
Fischer
J E
JE
D000818:Animals; D003358:Cosmetics / Q000737:chemistry / Q000378:metabolism / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D005069:Evaluation Studies as Topic; D005233:Fatty Alcohols / Q000737:chemistry / Q000633:toxicity*; D005260:Female; D006801:Humans; D007928:Lethal Dose 50; D008297:Male; D011092:Polyethylene Glycols / Q000737:chemistry / Q000633:toxicity*; D011897:Random Allocation; D051381:Rats; D011919:Rats, Inbred Strains; D019155:Veterinary Drugs / Q000737:chemistry / Q000378:metabolism / Q000633:toxicity*
D003358:Cosmetics; D005233:Fatty Alcohols; D019155:Veterinary Drugs; D011092:Polyethylene Glycols; C114849:crodamol PMP